Skip to main content
    I

    Inovio Pharmaceuticals Inc (INO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.40
    -0.03 (-2.10%)

    Market Cap: $267.85M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Inovio Pharmaceuticals Inc (INO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Inovio Pharmaceuticals reported revenue of $65.34K for the fiscal year ended Dec 31, 2025, down 70.0% from the year before. That year, net income was -$84.95M with a net margin of -130000.0%, operating cash flow was -$88.63M and free cash flow was -$88.92M. The quarter ended Sep 30, 2026 had revenue of $298.90K and net income of -$49.20M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $35.37M, a compound annual decline of 50.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$65.34K-70.0%100.0%-132871.3%-130000.0%
    Dec 2024$217.76K-73.8%100.0%-51616.9%-49254.3%
    Dec 2023$832.01K-91.9%100.0%-17300.3%-16239.9%
    Dec 2022$10.26M+478.2%100.0%-2607.4%-2726.7%
    Dec 2021$1.77M-76.1%100.0%-16972.3%-17109.9%
    Dec 2020$7.41M+80.2%100.0%-1674.2%-2259.7%
    Dec 2019$4.11M-86.5%100.0%-2702.1%-2931.8%
    Dec 2018$30.48M-27.8%100.0%-308.7%-318.1%
    Dec 2017$42.22M+19.4%100.0%-198.1%-208.9%
    Dec 2016$35.37MN/A100.0%-215.5%-208.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$65.34K$217.76K$832.01K$10.26M$1.77M$7.41M$4.11M$30.48M$42.22M$35.37M
    Gross profit$65.34K$217.76K$832.01K$10.26M$1.77M$7.41M$4.11M$30.48M$42.22M$35.37M
    Research and development$54.21M$75.62M$86.68M$187.65M$249.24M$94.25M$88.02M$95.26M$98.57M$88.71M
    Operating income-$86.82M-$112.40M-$143.94M-$267.57M-$301.22M-$124.08M-$111.11M-$94.09M-$83.64M-$76.24M
    Net income-$84.95M-$107.25M-$135.12M-$279.82M-$303.66M-$167.47M-$120.55M-$96.97M-$88.21M-$73.74M
    EBITDA-$83.34M-$108.15MN/AN/A-$297.73MN/A-$106.86M-$90.00M-$80.05M-$72.88M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$298.90K$0$0-$65.34K$0$0$65.34K$116.99K$0$100.76K$0$102.65K
    Gross profit$298.90K$0$0-$754.05K$0$0$65.34K$116.99K$0$100.76K$0$102.65K
    Operating income-$19.52M-$18.62M-$21.95M-$17.48M-$21.21M-$23.08M-$25.05M-$20.37M-$27.35M-$33.20M-$31.48M-$27.39M
    Net income-$49.20M-$6.01M-$19.68M$3.76M-$45.50M-$23.52M-$19.69M-$19.38M-$25.17M-$32.24M-$30.47M-$25.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.82M by $41.45M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$74.31M$113.20M$170.95M$348.53M$495.94M$539.77M$143.95M$131.11M$187.24M$173.71M
    Current assets$61.12M$97.83M$153.11M$315.24M$448.44M$471.17M$94.20M$87.81M$138.36M$124.60M
    Cash and equivalents$44.27M$65.81M$14.31M$46.33M$71.14M$250.73M$22.20M$23.69M$23.79M$19.14M
    Total liabilities$50.21M$44.69M$53.60M$126.17M$96.27M$78.63M$138.55M$44.08M$44.75M$50.33M
    Short-term debt$2.82M$2.50M$16.77M$0$2.60M$2.33M$2.07MN/A$25.20M$20.49M
    Long-term debtN/AN/AN/A$16.61M$14.96M$18.66M$77.02M$0$0$0
    Shareholder equity$24.10M$68.50M$117.35M$222.36M$399.67M$461.14M$3.44M$86.94M$142.39M$123.28M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$60.14M$49.39M$49.78M$74.31M$69.39M$68.24M$87.27M$113.20M$107.06M$133.80M$129.11M$170.95M
    Total liabilities$94.06M$45.02M$43.71M$50.21M$77.11M$39.71M$36.02M$44.69M$33.52M$37.06M$34.67M$53.60M
    Cash and equivalents$46.96M$31.53M$26.27M$44.27M$36.57M$24.35M$39.92M$65.81M$21.69M$34.39M$19.60M$14.31M
    Shareholder equity-$33.92M$4.37M$6.07M$24.10M-$7.72M$28.53M$51.25M$68.50M$73.54M$96.74M$94.44M$117.35M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$88.63M-$104.08M-$124.37M-$216.22M-$215.71M-$177.98M-$97.85M-$73.55M-$63.21M-$62.56M
    Capital expenditures$285.70K$487.83K$320.90K$969.15K$1.23M$1.52M$987.93K$2.09M$10.29M$2.74M
    Free cash flow-$88.92M-$104.56M-$124.69M-$217.18M-$216.94M-$179.50M-$98.84M-$75.64M-$73.50M-$65.29M
    Dividends paidN/AN/AN/AN/AN/A$3.86M$93.24MN/A$0$0
    Investing cash flow$14.04M$104.07M$87.36M$109.59M-$175.34M-$58.80M-$9.04M$42.42M-$27.83M$16.27M
    Financing cash flow$53.05M$51.48M$5.00M$81.84M$211.50M$465.28M$105.40M$31.04M$95.69M$7.79M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$15.27M-$18.05M-$21.59M-$19.37M-$21.57M-$20.81M-$26.87M-$19.66M-$27.44M-$28.21M-$28.76M-$26.28M
    Capital expendituresN/AN/A$0$127.44K$67.95K$30.93K$59.37K$0$487.83K$452.25K$35.58K$320.90K
    Free cash flowN/AN/A-$21.59M-$19.50M-$21.64M-$20.84M-$26.93M-$19.66M-$27.93M-$28.66M-$28.80M-$26.60M
    Last 12 quarters

    Frequently Asked Questions About INO

    What is Inovio Pharmaceuticals' annual revenue?

    Inovio Pharmaceuticals reported revenue of $65.34K for the fiscal year ended Dec 31, 2025.

    How fast is Inovio Pharmaceuticals' revenue growing?

    Revenue was down 70.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -81.5%.

    Is Inovio Pharmaceuticals profitable?

    No. Inovio Pharmaceuticals reported net income of -$84.95M for the fiscal year ended Dec 31, 2025, with a net margin of -130000.0%.

    How much free cash flow does INO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$88.63M minus capital expenditures of $285.70K produced free cash flow of -$88.92M.

    How much debt does Inovio Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.82M and cash and equivalents of $44.27M.